PRESS RELEASE / NEWS
RaQualia Pharma and Veritas In Silico announce that both companies have achieved the milestone in a joint research collaboration for mRNA-targeted small molecule drug discovery
December 14, 2023 –RaQualia Pharma Inc. (Head Office: Nagoya, Aichi, Japan; “RaQualia Pharma”) and Veritas In Silico Inc. (Head Office: Shinagawa, Tokyo, Japan; “Veritas In Silico”) announced today that they have achieved the milestone in the joint research agreement which both companies executed for mRNA-targeted small molecule drug discovery on December 22, 2022.
RaQualia Pharma, as an R&D-oriented biotech company, has been engaged in small molecule drug discovery technologies. Veritas In Silico has established a drug discovery platform, ibVISⓇ, that enables the identification of target structures in mRNA and the design and identification of small molecule drugs for these targets. In the research collaboration between RaQualia Pharma and Veritas In Silico, they are creating novel small molecule drugs against several mRNAs in oncology. Now, both companies have achieved the milestone with the criteria which are set in the agreement. RaQualia Pharma pays the milestone payment to Veritas In Silico, but the amount and condition of this achievement is not disclosed.
“We are thrilled to unveil one of the outcomes of our efforts to strengthen the drug discovery value chain. The close collaboration between Veritas in Silico and RaQualia Pharma has enabled this milestone in less than one year since the start of the collaboration. We also believe this is a significant achievement in the Japanese drug discovery ecosystem as a collaboration between biotech companies. We will continue to work with Veritas in Silico to create breakthrough new drugs.” said Hirobumi Takeuchi, President and CEO of RaQualia Pharma.
“We are very pleased to have achieved this milestone in our research collaboration with RaQualia Pharma. We look forward to continuing to work with RaQualia Pharma and contribute to the collaborative research using our ibVISⓇ platform technology, which is one of our strengths, and expect to achieve further results that will lead to the creation of new drugs.” said Shingo Nakamura, Representative Director and CEO of Veritas In Silico.
RaQualia Pharma and Veritas In Silico will work together to provide the new treatment options to patients as quickly as possible through this strong collaboration, and to make further contributions to improve the quality of life of patients.